Citation

Hwang CS, Turner LW, Kruszewski SP, Kolodny A, Alexander GC. Clin. J. Pain 2015; 32(4): 279-284.

Affiliation

*Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland †Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland ‡Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland §Stefan P. Kruszewski, MD & Associates, Harrisburg, Pennsylvania ∥Phoenix House Foundation, New York, New York ¶Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts #Global Institute for Public Health, New York University, New York **Division of General Internal Medicine, Department of Medicine, Johns Hopkins Medicine, Baltimore, Maryland.

Copyright

(Copyright © 2015, Lippincott Williams and Wilkins)

DOI

10.1097/AJP.0000000000000268

PMID

26102320

Abstract

OBJECTIVES: Physicians are a key stakeholder in the epidemic of prescription opioid abuse. Therefore, we assessed their knowledge of opioid abuse and diversion, as well as their support for clinical and regulatory interventions to reduce opioid-related morbidity and mortality.

METHODS: We conducted a nationally representative postal mail survey of 1000 practicing internists, family physicians, and general practitioners in the United States between February and May 2014.

RESULTS: The adjusted response rate was 58%, and all physicians (100%) believed that prescription drug abuse was a problem in their communities. However, only two-thirds (66%) correctly reported that the most common route of abuse was swallowing pills whole while nearly one-half (46%) erroneously reported that abuse-deterrent formulations were less addictive than their counterparts. In addition, a notable minority of physicians (25%) reported being not at all or only slightly concerned about the potential for opioid diversion from the licit to the illicit market when this practice is in fact common at all levels of the pharmaceutical supply chain. Most physicians supported clinical and regulatory interventions to reduce prescription opioid abuse, including the use of patient contracts (98%), urine drug testing (90%), requiring prescribers to check a centralized database prior to prescribing opioids (88%), and instituting greater restrictions on the marketing and promotion of opioids (77-82%). Despite this, one-third of physicians (33%) believed that interventions to reduce prescription opioid abuse had a moderate or large effect on preventing patients' clinically appropriate access to pain treatment.

DISCUSSION: Although physicians are unaware of some facets of prescription opioid-related morbidity, most support a variety of clinical and regulatory interventions to improve the risk-benefit balance of these therapies.

Language: en